Abstract Treatment of tuberculosis (TB) involves the administration of anti-mycobacterial
drugs for several months. The emergence of drug-resistant strains of Mycobacterium …

Tuberculosis is a far-reaching, high-impact disease. It is among the top ten causes of death
worldwide caused by a single infectious agent; 1.6 million tuberculosis-related deaths were …

The hallmark of tuberculosis (TB) is the formation of immune cell-enriched aggregates called
granulomas. While granulomas are pathologically diverse, their tissue-wide heterogeneity …

Mycobacterium tuberculosis (M. tb) is a bacterial pathogen that has evolved in humans, and
its interactions with the host are complex and best studied in humans. Myriad immune …

Research on the pathogenesis of tuberculosis (TB) has been hamstrung for half a century by
the paradigm that granulomas are the hallmark of active disease. Human TB, in fact …

BACKGROUND Matrix metalloproteinases (MMPs) are key regulators of tissue destruction in
tuberculosis (TB) and may be targets for host-directed therapy. We conducted a phase II …

Background and aims Multi drug or rifampicin resistant tuberculosis (MDR/RR-TB) is a major
burden to TB prevention and eradication globally. Since 2016, WHO guidelines have …

Bovine tuberculosis (bTB) is one of the globe's most common, multihost zoonoses and
results in substantial socioeconomic costs for governments, farming industries, and tax …

Background: To contain the pandemic of COVID-19, China has implemented a series of
public health interventions that impacted the tuberculosis control substantially, but these …

Tuberculosis (TB) has been responsible for the greatest number of human deaths due to an
infectious disease in general, and due to antimicrobial resistance (AMR) in particular. The …